Alzheimer's is the most common form of dementia and progresses in three stages: the preclinical stage without symptoms; the prodromal stage with mild cognitive impairment and the dementia stage with functional impairment. Advanced age is the predominant risk of Alzheimer's with the disease manifesting mainly in individuals aged 65 years and older. The percentage of individuals with Alzheimer's increases with age: approximately 5%, 13% and 33% of people have Alzheimer's dementia aged 65 to 74 years, 75 to 84 years and 85 years and older, respectively. The World Health Organization has estimated that

Alzheimer's and other dementias affect more than 55 million people worldwide and impose a global annual economic burden of USD 1.3 trillion in associated healthcare costs. This review provides an update on current treatment options for Alzheimer's disease and an insight into key selected significant therapeutic developments with data sourced from IQVIA Pipeline Link, a proprietary drug pipeline database.

Please fill in your details on the left to download the article